Drugs / Flonoltinib
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07612306 | Jun → Oct 2026 expected | — | Chengdu Zenitar Biomedical Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06387966 | Mar → Aug 2024 | — | Chengdu Zenitar Biomedical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05115344 | Nov 2021 → Dec 2022 | myelofibrosis | Chengdu Zenitar Biomedical Technology Co., Ltd | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05153343 | Dec 2021 → Nov 2023 | myelofibrosis | Chengdu Zenitar Biomedical Technology Co., Ltd | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07443306 | Mar 2026 → Dec 2027 expected | — | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07232290 | Sep 2025 → Jul 2027 expected | acquired polycythemia vera | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06457425 | May 2024 → May 2026 overdue | — | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07317700 | Feb 2026 → Dec 2027 expected | — | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05713279 | Jan → Nov 2023 | COVID-19 | Chengdu Zenitar Biomedical Technology Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flonoltinib | “Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection” NCT05713279 ↗ |
| Known as | Flonoltinib Maleate | “Flonoltinib Maleate (FM), a triple target inhibitor of JAK2/FLT3/CDK6, has the potential to inhibit JAK2 signaling pathway activity and treat bone marrow proliferative tumors.” NCT07232290 ↗4“Flonoltinib maleate (FM), a novel JAK2/FLT3/CDK6 inhibitor, shows preliminary potential in improving hematologic parameters and reducing fibrosis.” PMID 41883618 ↗ Mar 2026 “Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).” NCT05115344 ↗ “Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).” NCT05153343 ↗ “A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis” NCT07317700 ↗ |
| Action | Inhibit | “FM is a dual target inhibitor of JAK2/FLT3.” NCT05153343 ↗ |
| Route | Oral | “single and repeated oral administration of flonoltinib maleate tablets” NCT05115344 ↗ |
| Target | JAK2 | “FM targets Janus kinase 2 (JAK2)” NCT05153343 ↗ |